Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meprotixol is a small molecule drug classified as a thioxanthene derivative. It acts primarily as an antitussive (cough suppressant) and has also been used in the treatment of rheumatic diseases. Meprotixol exhibits potent antitussive activity, slight central depressive effects, and can reduce spontaneous motor activity in animal models, though it is much less potent than neuroleptics such as chlorpromazine. Additionally, it demonstrates broncho-spasmolytic effects against serotonin-induced spasms and shows some anti-inflammatory properties by inhibiting edema and exudation in experimental models. Its precise mechanism of action as an antitussive is not fully elucidated but may involve central nervous system pathways[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meprotixol.